Ovarian Cancer Clinical Trial
Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer
Summary
The purpose of the study is to compare the efficacy and safety of 2 doses of drug AZD2281 against liposomal doxorubicin to see which is effective and well tolerated in treating patients with measurable BRCA1- or BRCA2-positive advanced ovarian cancer and who have failed previous platinum therapy.
Eligibility Criteria
Inclusion Criteria:
Advanced ovarian cancer with positive BRCA1 or BRCA2 status
Progressive or recurrent disease after platinum-based chemotherapy
Measurable disease by RECIST
Exclusion Criteria:
Previous anthracycline treatment
Brain metastases
Less than 28 days since last treatment used to treat the disease
Considered a poor medical risk due to a serious uncontrolled disorder
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 24 Locations for this study
Los Angeles California, 90048, United States
San Francisco California, 94115, United States
Boca Raton Florida, 33428, United States
Boston Massachusetts, 02115, United States
New York New York, 10065, United States
Houston Texas, 77030, United States
East Melbourne , 3002, Australia
Melbourne, Parkville , VIC 3, Australia
Randwick , 2031, Australia
Leuven , 3000, Belgium
Köln , 50937, Germany
München , 81377, Germany
Haifa , 31096, Israel
Ramat Gan , 52621, Israel
Tel Aviv , 64239, Israel
Szczecin , 70-11, Poland
Barcelona , 08035, Spain
Hospitalet deLlobregat , 08907, Spain
Lund , 22185, Sweden
Cambridge , CB2 0, United Kingdom
Edinburgh , EH4 2, United Kingdom
London , SE1 9, United Kingdom
Manchester , M20 4, United Kingdom
Sutton , SM2 5, United Kingdom
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.